Edition:
United States

Acorda Therapeutics Inc (ACOR.OQ)

ACOR.OQ on NASDAQ Stock Exchange Global Select Market

25.80USD
16 Feb 2018
Change (% chg)

$0.70 (+2.79%)
Prev Close
$25.10
Open
$26.05
Day's High
$26.65
Day's Low
$25.50
Volume
189,452
Avg. Vol
198,704
52-wk High
$33.00
52-wk Low
$13.65

Chart for

About

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra... (more)

Overall

Beta: 1.59
Market Cap(Mil.): $1,206.08
Shares Outstanding(Mil.): 46.75
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Acorda Therapeutics Q4 Adj Shr $0.61

* AMPYRA NET REVENUE IS EXPECTED TO BE $330 MILLION TO $350 MILLION IN 2018

Feb 15 2018

Acorda Therapeutics exploring sale: WSJ

Acorda Therapeutics is exploring a sale of the company, the Wall Street Journal reported, citing people familiar with the matter.

Jan 05 2018

BRIEF-Acorda Therapeutics Is Exploring A Potential Sale - WSJ, Citing Sources

* ACORDA THERAPEUTICS IS EXPLORING A POTENTIAL SALE - WSJ, CITING SOURCES Source text - http://on.wsj.com/2Ay49BA Further company coverage: (Bengaluru Newsroom)

Jan 05 2018

BRIEF-Acorda Resubmits New Drug Application For INBRIJA

* ACORDA RESUBMITS NEW DRUG APPLICATION FOR INBRIJA™ (CVT-301, LEVODOPA INHALATION POWDER)

Dec 07 2017

UPDATE 3-Acorda Therapeutics scraps Parkinson's drug after deaths

* Last week company reported five deaths in tozadenant studies

Nov 20 2017

Acorda Therapeutics scraps Parkinson's drug after deaths

Acorda Therapeutics Inc said on Monday it would stop developing its Parkinson's disease drug, tozadenant, less than a week after the company reported deaths in key studies testing the treatment.

Nov 20 2017

Acorda Therapeutics scraps development of Parkinson's disease drug

Nov 20 Acorda Therapeutics Inc said on Monday it would terminate developing its drug to treat Parkinson's disease, a week after the drugmaker reported five deaths in key studies testing the treatment.

Nov 20 2017

BRIEF-Acorda announces royalty monetization transactions for $53 mln

* Acorda announces royalty monetization transactions for $53 million

Nov 17 2017

Acorda reports five deaths in Parkinson's trial, shares plunge

Acorda Therapeutics Inc said five people died in trials for its Parkinson's disease drug, the latest in a series of setbacks for the drugmaker, sending its shares down 38 percent.

Nov 15 2017

UPDATE 4-Acorda reports five deaths in Parkinson's trial, shares plunge

* Shares tank nearly 40 pct (Recasts, adds CEO and analyst comments, updates shares)

Nov 15 2017

Earnings vs. Estimates